NovaBay Shareholder Information .... Investor O

NovaBay Shareholder Information ....

Investor Overview

NovaBay Pharmaceuticals is a clinical stage biotechnology company focused on developing its proprietary and patented topical Aganocide® compounds, which are novel, synthetic anti-infective product candidates with equivalent activity to the active antimicrobial molecules generated within white blood cells. NovaBay's topical Aganocide compounds are being developed to treat and prevent a wide range of infections without causing bacterial resistance. NovaBay has internal development programs aimed at addressing hospital infections, chronic non-healing wounds, UCBE and onychomycosis.

NovaBay has entered into and recently expanded an agreement with Galderma S.A. to develop and commercialize Aganocide compounds in acne, impetigo and other dermatological indications.

Transfer Agent

The transfer agent and registrar for our common stock is Computershare Trust Company, N.A. with the following contact information:

For standard US postal mail
Computershare Trust Company, N.A.  
Po Box 43070
Providence, RI 02940-3070

For overnight/express delivery
Computershare Trust Company, N.A.
250 Royall Street
Canton, MA 02021

For DWAC instructions provided to brokers
FAST Transfer Agent number – 50173

Telephone and Fax
Toll free in the US +1 800 962 4284
Telephone +1 303-262-0600
Fax +1 303-262-0700

Website
www.computershare.com

eMail inquiries
web.queries@computershare.com

Investor Relations contacts
Theresa Granados
(510) 899-8870 
Email Theresa

Events

May 18, 2011
Archive of Conference call Re: Results from Phase 2 Clinical Study for the Treatment of Adenoviral Conjunctivitis
 Click Here To Listen

September 21, 2010
Behzad Khosrovi, M.A., Ph.D. of NovaBay Interviewed on HealthRadio.net about Antibiotic Resistance 

July 21, 2010
Archive of Conference call Re: Impetigo Clinical Trial Results
 Click Here To Listen

July 10-14, 2010
Ron Najafi, NovaBay CEO, to be Plenary Speaker at Controlled Release Society (CRS) Annual Meeting

April 19, 2010
Archive of Conference call Re: CAUTI Trial Pipeline Update
 Click Here To Listen

March 25, 2010

Catheter-Associated Urinary Tract Infection Expert, David Stickler, Interviewed
 Click Here To Listen

February 09, 2010

NovaBay CEO Ron Najafi Presents at BIO CEO & Investor Conference
 Click Here To Listen

January 10, 2010

Founding Director of UCLA's Urological Center and NovaBay SAB Member, Bernard Churchill, M.D., Interviewed
 Click Here to Listen

December 22, 2009

World-Renowned Biofilm Expert and NovaBay SAB Member, William Costerton, Ph.D., Interviewed
 Click Here to Listen

March 25, 2009

NovaBay and Galderma enter into Global Agreement to Develop and Commercialize NovaBay’s Novel Aganocide Drugs for Major Dermatological Conditions 
 View this webcast Wednesday, March 25, 2009 at 8:00AM PT

August 7, 2008

NovaBay Pharmaceuticals, Inc. Featured on KGO-TV San Francisco
  The video can be viewed here

Corporate Governance

NovaBay is committed to good governance and business practices. High standards of corporate governance are a priority at NovaBay. The Board and management team believe that commitment to excellence and integrity is essential to the long-term success of the Company and to sustaining strong stakeholder relationships. NovaBay uses a variety of policies, programs and practices to manage corporate governance. 

Code of Business Conduct and Ethics 
Audit Committee Charter 
Whistleblower Policy 
Corporate Governance Guidelines 
Compensation Committee Charter 
Nomination and Corporate Governance Committee Charter  
Composition of Board Committees